Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PBH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPrestige Consumer Healthcare closes $150M LaCorium acquisition, refinances $400M debt at higher rate
Filed July 6, 2026 · Period ending June 30, 2026 · ~1 min read
Key Changes
-
high
Closed acquisition of LaCorium Health Australia for $150M cash on July 1, 2026. LaCorium generates ~$40M annual revenue with brands including Dermal Therapy and Flexitol, expected to produce ~$12M EBITDA with synergies.
Exhibit 99.2 view on EDGAR → -
high
Priced $400M senior notes at 6.25% due 2034 to refinance all $400M of 5.125% notes due 2028. Refinancing extends maturity six years but increases annual interest expense by ~$4.5M.
Exhibit 99.2 view on EDGAR → -
medium
Amended term loan credit agreement to permit up to $95M in additional borrowings to partially finance the LaCorium acquisition and related fees.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
low
Will report Q1 fiscal 2027 earnings on August 6, 2026, before market open, with conference call at 8:30 a.m. ET.
Exhibit 99.2 view on EDGAR →
Summary
Prestige Consumer Healthcare completed its $150 million acquisition of LaCorium Health Australia on July 1, 2026, adding a therapeutic skin care portfolio generating approximately $40 million in annual revenue. The company financed the deal with cash on hand, existing credit facilities (including up to $95 million in new term loan capacity), and a $400 million senior notes offering. The debt refinancing extends maturity from January 2028 to 2034 but at a higher cost: the new 6.25% notes replace 5.125% notes, increasing annual interest expense by approximately $4.5 million.
This trade-off buys the company six additional years of runway and eliminates near-term refinancing risk, though at a material cost premium reflecting current market conditions. The LaCorium acquisition is expected to generate approximately $12 million in EBITDA including synergies once fully integrated, providing incremental cash flow to service the higher debt cost.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Prestige Consumer Healthcare borrowed up to $95M in additional term loans to finance the LaCorium Health Australia acquisition.
Added in current filing · verify on EDGAR →
On July 1, 2026 (the “Closing Date”), Prestige Consumer Healthcare Inc. (the “Company”) and its wholly-owned subsidiary, Prestige Brands, Inc. (the “Borrower”), entered into an amendment (the “Amendment”) to that certain Term Loan Credit Agreement (the “Term Loan Credit Agreement”) by and among the Company, the Borrower, certain other subsidiaries of the Company as guarantors, Citibank, N.A. as administrative agent, the lenders party thereto and Citibank, N.A., Barclays Bank PLC, Morgan Stanley Senior Funding Inc., Goldman Sachs Bank USA and RBC Capital Markets, as joint lead arrangers and joint bookrunners. Under the Amendment, the Borrower is permitted to borrow additional term loans in an amount not to exceed $95.0 million that may be used by the Borrower to finance, in part, the previously announced acquisition of LaCorium Health Australia Pty Limited, Stantail Trading Pty Limited, Stantail International Pty Limited, Brands Worldwide Holdings I.P. Pty Limited, and Laderma Holdings Pty Limited, each an Australian company (the “LaCorium Acquisition”), together with fees and expenses incurred in connection with the LaCorium Acquisition.
The company amended its existing term loan credit agreement to permit borrowing up to $95 million in additional term loans. These proceeds will partially finance the previously announced acquisition of LaCorium Health Australia and related entities, along with associated transaction fees and expenses. The amendment was executed on July 1, 2026, with Citibank serving as administrative agent and a syndicate of major banks as arrangers.
Event · Item 7.01 — Regulation FD Disclosure
Prestige Consumer Healthcare completed the LaCorium Acquisition and priced a $400 million senior unsecured notes offering due 2034.
Added in current filing · verify on EDGAR →
the Company issued a press release announcing the completion of the LaCorium Acquisition and the pricing of the private offering of the Notes
Prestige Consumer Healthcare completed the acquisition of LaCorium on July 6, 2026.
Added in current filing · verify on EDGAR →
the Company issued a press release announcing the commencement of a private offering of $400,000,000 of senior unsecured notes due 2034 (the “Notes”)
The company commenced and subsequently priced a private offering of $400 million in senior unsecured notes maturing in 2034. The filing does not disclose the interest rate, pricing terms, or intended use of proceeds, though the timing suggests the proceeds may be related to financing the LaCorium Acquisition.
Event · Exhibit 99.1
Prestige announces $400M senior notes offering to refinance 2028 debt at lower rate, extending maturity to 2034.
Added in current filing · view on EDGAR →
Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), intends to offer, subject to market and other conditions, up to $400 million in aggregate principal amount of new senior notes due 2034 (the “notes”) in a private offering. The notes will be senior unsecured obligations of Prestige Brands and will be guaranteed by the Company and certain of its domestic subsidiaries.
Prestige Brands is launching a private offering of up to $400 million in new senior notes maturing in 2034. These notes will be senior unsecured obligations guaranteed by the parent company and certain domestic subsidiaries. The offering is subject to market conditions and will be conducted as a private placement to qualified institutional buyers.
Added in current filing · view on EDGAR →
Prestige Brands expects to give notice of its intention to redeem the 2028 notes pursuant to the indenture governing the 2028 notes, at a redemption price equal to 100.0% of the principal amount thereof, plus accrued and unpaid interest to the date of redemption. The redemption of the 2028 notes is conditioned on the completion of an offering of new unsecured senior notes in an aggregate principal amount of at least $400 million (the “Financing Condition”). Prestige Brands may waive the Financing Condition in its sole discretion.
The company will redeem the 2028 notes at par (100% of principal) plus accrued interest. The redemption is conditioned on successfully completing an offering of at least $400 million in new senior notes, though the company can waive this condition at its discretion. This structure protects the company from being obligated to redeem the old notes if the new financing fails to materialize.
Event · Exhibit 99.2
Prestige Consumer Healthcare closed $150M LaCorium Health acquisition, priced $400M senior notes to refinance 2028 debt, and set Q1 FY2027 earnings date.
Added in current filing · view on EDGAR →
The Company will issue its fiscal 2027 first quarter earnings release on Thursday, August 6, 2026 before the market open. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.
Prestige announced it will report first quarter fiscal 2027 earnings results on August 6, 2026, before market open, followed by a conference call at 8:30 a.m. ET. This provides investors with the scheduled date for the company's next quarterly financial disclosure.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 10, 2026 · How we verify